Europe
Cristal Therapeutics, a clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced three upcoming poster presentations that highlight CPC634 positive data from its three phase 1 safety and biodistribution studies at the ASCO 2019 meeting, Chicago, Illinois May 31st - June 4th.
Syncona, a London-based healthcare investment company, committed £34 million and UCL Technology Fund invested £1 million.
NAYZILAM was approved to treat frequent seizure cluster episodes in epilepsy patients.
Here’s a roundup of some of the top clinical trial news from the previous week.
The collaboration will focus on Inovio’s VGX-3100, which stimulates a specific immune response to HPV-16 and HPV-18, targeting the infection and causing destruction of precancerous cells.
Primary analysis of L-MIND trial of tafasitamab (MOR208) plus lenalidomide in relapsed or refractory (r/r) DLBCL confirms overall strong data reported previously from this trial
MorphoSys AG today announced results from the primary analysis (cut-off date November 30, 2018) of the ongoing single-arm phase 2 clinical trial known as L-MIND.
FDA Cleared and CE Marked, Telescope Enters Global Market with Design Innovations to Enable Smooth Delivery of Coronary Stents and Balloons
Pharming Group N.V. today supports world “hae day :-)”.
Bittium exhibits its products and solutions for neurophysiology at Post Cardiac Arrest Care 2019
PRESS RELEASES